HUMA vs. EVLV, DSKE, BARK, SST, BODY, SWTX, DNLI, ACLX, APGE, and TWST
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Evolv Technologies (EVLV), Daseke (DSKE), BARK (BARK), System1 (SST), Beachbody (BODY), SpringWorks Therapeutics (SWTX), Denali Therapeutics (DNLI), Arcellx (ACLX), Apogee Therapeutics (APGE), and Twist Bioscience (TWST).
Humacyte (NASDAQ:HUMA) and Evolv Technologies (NASDAQ:EVLV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.
Humacyte currently has a consensus price target of $8.00, suggesting a potential upside of 10.04%. Evolv Technologies has a consensus price target of $5.65, suggesting a potential upside of 129.67%. Given Evolv Technologies' higher possible upside, analysts plainly believe Evolv Technologies is more favorable than Humacyte.
In the previous week, Humacyte had 17 more articles in the media than Evolv Technologies. MarketBeat recorded 17 mentions for Humacyte and 0 mentions for Evolv Technologies. Humacyte's average media sentiment score of 0.69 beat Evolv Technologies' score of 0.00 indicating that Humacyte is being referred to more favorably in the media.
44.7% of Humacyte shares are owned by institutional investors. Comparatively, 66.7% of Evolv Technologies shares are owned by institutional investors. 23.1% of Humacyte shares are owned by insiders. Comparatively, 11.2% of Evolv Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Humacyte has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Evolv Technologies has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
Humacyte received 7 more outperform votes than Evolv Technologies when rated by MarketBeat users. However, 83.33% of users gave Evolv Technologies an outperform vote while only 51.52% of users gave Humacyte an outperform vote.
Evolv Technologies has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Evolv Technologies, indicating that it is currently the more affordable of the two stocks.
Humacyte has a net margin of 0.00% compared to Evolv Technologies' net margin of -106.93%. Evolv Technologies' return on equity of -45.57% beat Humacyte's return on equity.
Summary
Evolv Technologies beats Humacyte on 9 of the 17 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
